Literature DB >> 9147407

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

M Otto1, J Wiltfang, H Tumani, I Zerr, M Lantsch, J Kornhuber, T Weber, H A Kretzschmar, S Poser.   

Abstract

Creutzfeldt-Jakob disease (CJD) is a rare, fatal, neurodegenerative disease caused by a transmissible agent designated as proteinaceous infectious agent (prion). Searching for biochemical markers of CJD, we analysed cerebrospinal fluid (CSF) samples of 53 patients for tau-protein using an enzyme linked immunoassay (ELISA). In a group of 21 patients with definite CJD seen in the German case control study for CJD, tau-protein concentrations in CSF were significantly higher than in two control-groups of patients with other diseases (median 13,153 pg/ml, range 1,533-27,648 pg/ml; P = 0.0001). One group comprised 19 patients who were seen in the same study and were diagnosed as having other dementing diseases (tau concentration: median 558 pg/ml, range 233-1,769 pg/ml). The second control group comprised 13 patients from our hospital with no dementing disease (tau concentration: median 296 pg/ml, range 109-640 pg/ml). We conclude that determination of tau protein levels in CSF is a useful marker for laboratory diagnosis of CJD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9147407     DOI: 10.1016/s0304-3940(97)00215-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  70 in total

1.  Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease.

Authors:  M Seipelt; I Zerr; R Nau; B Mollenhauer; S Kropp; B J Steinhoff; C Wilhelm-Gössling; C Bamberg; R W Janzen; P Berlit; F Manz; K Felgenhauer; S Poser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

2.  Analysis of the exon 1 polymorphism in the Tau gene in transmissible spongiform encephalopathies.

Authors:  Raquel Sánchez-Valle; Pau Pastor; Jordi Yagüe; Teresa Ribalta; Francesc Graus; Eduardo Tolosa; Albert Saiz
Journal:  J Neurol       Date:  2002-07       Impact factor: 4.849

Review 3.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

4.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

5.  Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.

Authors:  David J Irwin; Alberto Lleó; Sharon X Xie; Corey T McMillan; David A Wolk; Edward B Lee; Viviana M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman
Journal:  Ann Neurol       Date:  2017-08-19       Impact factor: 10.422

Review 6.  Biomarkers related to aging in human populations.

Authors:  Eileen Crimmins; Sarinnapha Vasunilashorn; Jung Ki Kim; Dawn Alley
Journal:  Adv Clin Chem       Date:  2008       Impact factor: 5.394

Review 7.  Progress update: fluid and imaging biomarkers in Alzheimer's disease.

Authors:  Courtney L Sutphen; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2013-09-05       Impact factor: 13.382

8.  Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.

Authors:  Silvia Koscova; Dana Zakova Slivarichova; Ivana Tomeckova; Katarina Melicherova; Martin Stelzer; Alzbeta Janakova; Dana Kosorinova; Girma Belay; Eva Mitrova
Journal:  Mol Neurobiol       Date:  2016-09-24       Impact factor: 5.590

9.  Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.

Authors:  Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; Kaj Blennow; James B Brewer; Anders M Dale
Journal:  Cereb Cortex       Date:  2010-01-04       Impact factor: 5.357

Review 10.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.